progression free survival

0:43:25

36 First Line Therapy: Monitoring Success, Maintenance, & Disease Progression

0:04:07

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide,...

0:10:16

Is Progression-Free Survival without Overall Survival Benefit Enough? (BMIC-043)

0:06:56

2020 TTF RARE Mutations QA PANEL Why Mutations Have Different Progression-Free Survival Averages

0:01:06

Patient-reported outcomes predict progression-free survival | Our Research

0:06:07

Introduction to endpoints in oncology clinical trials

0:03:18

Metastasis-directed radiation boosts progression-free survival in metastatic pancreatic cancer.

0:02:11

What is progression free survival (PFS) and overall survival (OS) in breast cancer?

0:04:03

Mogamulizumab demonstrates significant improvement in progression free survival for CTCL

0:01:59

Long-term disease-free survival in myeloma

0:05:40

Dr. Chapman 5 | Progression free survival (PFS) vs. Overall survival (OS).

0:02:36

Keytruda Plus Chemotherapy Improves Progression-Free Survival in Metastatic Breast Cancer

0:02:22

Progression free survival |Radiotherapy Edutech | Common terms in Oncology

0:07:27

Phase III study shows brentuximab improves progression-free survival in Hodgkin lymphoma

0:01:15

Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab

0:07:56

KEYNOTE-048: progression post next line for R/M HNSCC

0:01:13

How long can high-risk multiple myeloma patients survive without treatment?

0:03:02

Ibrutinib prolongs progression-free survival in elderly patients with untreated CLL

0:06:16

Atezolizumab added to chemotherapy prolongs progression free survival in bladder cancer

0:06:03

Progression-Free and Overall Survival Correlation in Relapsed CLL

0:02:32

Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab

0:11:19

New endpoints in clinical trials to better serve patients

0:03:59

OS vs PFS with Olaratumab

0:02:22

ADRIATIC: patterns of disease progression with durvalumab in LS-SCLC